Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC1419 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.5051 | 0.1071 | 0.0007 | 1.4251 | 0.82031 | 0.95841 |
HCC1419 | Alpelisib | PI3Ka | PI3K/mTOR | 0.66882 | -0.0020 | 0.3558 | 0.0157 | 0.3922 | 11.0132 | 0.94051 |
HCC1419 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0091784 | -0.4046 | 0.8523 | 0.0945 | 0.5809 | 0.022714 | 0.98223 |
HCC1419 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.1803 | 0.7242 | 0.0249 | 0.0000 | Inf | 0.37602 |
HCC1419 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0047477 | -0.1472 | 0.7635 | 0.0603 | 1.3112 | 0.0056144 | 0.99448 |
HCC1419 | Saracatinib | SRC | MAPK/nRTK | 0.91888 | -0.1146 | 0.2758 | 0.0128 | 0.8021 | 1.8388 | 0.98394 |
HCC1419 | ABT-737 | Bcl2/XL | Misc | 9.84 | 0.4715 | 0.0022 | 0.0163 | 5.0000 | 11.4973 | 0.95757 |
HCC1419 | Trametinib | MEK | MAPK/nRTK | 0.031029 | 0.4259 | 0.2875 | -0.0031 | 1.4893 | 0.0089457 | 0.98063 |
HCC1419 | Vorinostat | HDAC | Misc | 1.735 | -0.2557 | 0.1917 | 0.0407 | 2.1116 | 2.1704 | 0.99173 |
HCC1419 | Topotecan | Topo I | Chemotherapy | 0.0071886 | -0.7857 | 0.9904 | 0.1711 | 0.4002 | 0.11192 | 0.94532 |
HCC1419 | Etoposide | Topo II | Chemotherapy | 0.73579 | 0.0317 | 0.3201 | 0.0034 | 1.8770 | 0.70309 | 0.96133 |
HCC1419 | Dasatinib | BCR/ABL | MAPK/nRTK | 0.82399 | -0.1962 | 0.3189 | 0.0194 | 0.7548 | 2.3816 | 0.99358 |
HCC1419 | Luminespib | HSP90 | Misc | 0.0069643 | -0.2968 | 0.6506 | 0.1579 | 2.0439 | 0.0087353 | 0.99699 |
HCC1419 | Dinaciclib | pan CDK | Cell cycle | 0.026695 | -0.4761 | 0.5131 | 0.1238 | 5.0000 | 0.030191 | 0.99589 |
HCC1419 | Cisplatin | Chemo | Chemotherapy | 1.7988 | 0.0949 | 0.2293 | 0.0086 | 1.0769 | 2.0814 | 0.93793 |
HCC1419 | Volasertib | PLK | Cell cycle | 0.020718 | 0.0685 | 0.3636 | 0.0462 | 1.8241 | 0.018178 | 0.98538 |
HCC1419 | Doxorubicin | Chemo | Chemotherapy | 0.025082 | -0.4663 | 0.5904 | 0.0473 | 0.5199 | 0.10425 | 0.94593 |
HCC1419 | Palbociclib | CDK4/6 | Cell cycle | 0.48725 | 0.4414 | 0.2239 | -0.0054 | 1.2398 | 0.053717 | 0.97241 |
HCC1419 | Taxol | Chemo | Chemotherapy | 0.0052608 | 0.2143 | 0.4700 | 0.0981 | 2.1841 | 0.0040283 | 0.97754 |
HCC1419 | A-1210477 | Mcl-1 | Misc | 14.536 | 0.7081 | 0.0402 | 0.0018 | 1.8053 | 26.3399 | 0.8672 |
HCC1419 | AZD7762 | CHK1/2 | Cell cycle | 0.068618 | -0.0826 | 0.5614 | 0.1156 | 2.0553 | 0.072481 | 0.98917 |
HCC1419 | Cediranib | VEGFR/cKIT | RTK | 5.0599 | -0.0329 | 0.0545 | 0.0124 | 4.9952 | 5.1984 | 0.99032 |
HCC1419 | Cabozantinib | VEGFR2/MET | RTK | 10.7779 | 0.6224 | -0.0111 | -0.0016 | 5.0000 | 12.9768 | 0.90031 |
HCC1419 | Pictilisib | pan PI3K | PI3K/mTOR | 0.17196 | -0.2103 | 0.5118 | 0.0340 | 0.5444 | 0.61152 | 0.99425 |
HCC1419 | Ceritinib | ALK | RTK | 2.6149 | -0.8670 | 0.2083 | 0.0855 | 2.5745 | 4.0066 | 0.99248 |